New strategies will be necessary for biotechnology companies to thrive in the new era of personalized medicine but the healthcare system itself will also have to change according to a panel of biotechnology company representatives at the 2008 Wharton Health Care Business Conference. Leaving behind the ”blockbuster drug” mentality must be part of a new mindset for biotech companies going forward suggested one panelist. Others discussed stem cell research regulatory hurdles and competition within the industry.
Hosted on Acast. See acast.com/privacy for more information.
Knowledge at Wharton